Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vicor Technologies, a biotechnology company, has entered into a collaborative research agreement with the University of Rochester and the Catalan Institute of Cardiovascular Sciences in Barcelona to study sudden cardiac death.
Subscribe to our email newsletter
According to the agreement, Vicor’s PD2i cardiac analyzer will be used by University of Rochester personnel to identify which of the 651 congestive heart failure patients who participated in the Music trial suffered sudden cardiac death.
During the average 44 months Music trial participants were followed, 52 died from sudden cardiac death. Vicor expects to have the results of its Music trial data analysis during the second quarter of 2009.
David Fater, president and CEO of Vicor, said: “We are extremely excited to be able to have this opportunity to analyze the Music trial patient data with our PD2i cardiac analyzer. An archive of analyzable data such as this – which is unusual to obtain – is a major accomplishment, as it enables us to quickly and cost-effectively produce a statistically significant clinical dataset.”